Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 1:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1441–1464 of 3,872 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: FAST Clear all

Conditions: COVID-19
Interventions: Behavioral questionaires; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 8 Years and older
Enrollment: 338 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 2
States / cities: Greenville, North Carolina • Chattanooga, Tennessee

Conditions: Healthy
Interventions: Raltegravir, Fosamprenavir, Ritonavir; Drug
Lead sponsor: Garden State Infectious Disease Associates, PA; Other
Eligibility: 18 Years to 64 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Voorhees Township, New Jersey

Conditions: Type 2 Diabetes, Glucose Tolerance Impaired, Insulin Sensitivity
Interventions: REMD-477, Placebo Subcutaneous injection; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 70 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy
Interventions: Colchicine, Colchicine/Probenecid; Drug
Lead sponsor: Mutual Pharmaceutical Company, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Time Restricted Eating
Interventions: Time restricted eating; Behavioral
Lead sponsor: University of Oklahoma; Other
Eligibility: 21 Years and older
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Stroke
Interventions: Soft robotic exosuit, Propulsion neuroprosthesis; Device
Lead sponsor: Boston University Charles River Campus; Other
Eligibility: 18 Years to 80 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Kidney Failure, Chronic
Interventions: Lanthanum Carbonate, Sevelamer; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Cypress, California

Conditions: Helicobacter Pylori
Interventions: Bismuth quadruple therapy with optimized proton pump inhibitor (PPI), Bismuth quadruple therapy with standard proton pump inhibitor (PPI), Clarithromycin triple therapy with optimized proton pump inhibitor (PPI), Clarithromycin triple therapy with standard PPI, Standard bismuth quadruple therapy; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: San Diego, California

Conditions: Malocclusion
Interventions: Micro-osteoperforation, Anesthestic, Chlorhexidine; Device · Drug · Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 55 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Parkinson Disease, Gaucher Disease, Idiopathic Rapid Eye Movement Sleep Disorder
Interventions: Not listed
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 85 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Brain Metastases
Interventions: 18F-Fluciclovine (Axumin) PET/CT; Diagnostic Test
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 99 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Transient Ischemic Attack, Stroke
Interventions: Quality Improvement Program; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Not listed
Enrollment: 2,292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Down Syndrome, Cardiovascular Risk Factor, Atherosclerosis
Interventions: Evaluate vascular disease risk factors in children with Down Syndrome, Determine the associations between cardiovascular disease risk factors and markers of early atherosclerosis in children with Down Syndrome; Other
Lead sponsor: University of Utah; Other
Eligibility: 10 Years to 18 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Interstitial Cystitis, Painful Bladder Syndrome
Interventions: Lidocaine, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Hepatitis C
Interventions: HCV Screening; Other
Lead sponsor: Denver Health and Hospital Authority; Other
Eligibility: 18 Years and older
Enrollment: 147,533 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 3
States / cities: Denver, Colorado • Baltimore, Maryland • Jackson, Mississippi

Conditions: Physical Deconditioning, Mobility Decline
Interventions: Gerofit Power Training, Gerofit Standard of Care; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 65 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Healthy Volunteers in Fed and Fasted State
Interventions: Zelquistinel 3 mg, Zelquistinel 10 mg; Drug
Lead sponsor: Syndeio Biosciences, Inc; Industry
Eligibility: 18 Years to 59 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Cancer
Interventions: Ipatasertib (capsule), Ipatasertib (tablet); Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Hypogonadism
Interventions: Oral testosterone undecanoate (TU) (300 mg T equivalents/dose), Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (400 mg T equivalents/dose), Oral testosterone undecanoate (TU) (200 mg T equivalents/dose with and without food), Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (300 mg T equivalents/dose); Drug
Lead sponsor: Clarus Therapeutics, Inc.; Industry
Eligibility: 18 Years to 68 Years · Male only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 4
States / cities: Birmingham, Alabama • Los Angeles, California • San Antonio, Texas

Conditions: Cardiac Conduction and Repolarization
Interventions: Custirsen, Placebo, Moxifloxacin; Drug
Lead sponsor: Achieve Life Sciences; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 155 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Pharmacokinetics
Interventions: Acetylsalicylic Acid (Aspirin BAY1019036), Alka Seltzer Extra Strength, Aspirin Migraine, Aspirin Aspro; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Tick-Borne Encephalitis, Encephalitis, Tick-Borne, Tick-Borne Disease, Glycoprotein E, Flavivirus, NSI Protein, Flavivirus
Interventions: FSME-IMMUN 0.5ml Baxter; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2016
U.S. locations: 2
States / cities: Bethesda, Maryland • Hamilton, Montana

Conditions: Metabolic Syndrome
Interventions: Not listed
Lead sponsor: Epic Research & Diagnostics, Inc.; Industry
Eligibility: 21 Years to 85 Years
Enrollment: 193 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Scottsdale, Arizona

Conditions: Glioblastoma
Interventions: Temodar and Irinotecan; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Durham, North Carolina

Search by objective public record fields.

Rapid Acceleration for Diagnostics in Underserved Populations: Home Testing

An Interaction Study to Assess Drug Levels in Fasting Healthy Adult Subjects

Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DM

Bioequivalence Study of Colchicine Tablets

Cerebromicrovascular Effects of Time-Restricted Eating in Older Adults

Personalized Post-Stroke Gait Rehabilitation Interventions

Comparing Absorption of Dietary Phosphorus When Administering FOSRENOL® or RENVELA® in Healthy Adult Volunteers

Personalized vs Standard of Care Treatment for Helicobacter Pylori Eradication Among Veterans

Alveolar Microperforation for Inflammation-Enhanced Tooth Movement During Orthodontic Treatment

Detecting Dopaminergic Deficits in Individuals At-risk for Parkinsonism

Feasibility of 18F-Fluciclovine PET/CT to Identify Brain Metastasis

Protocol-guided Rapid Evaluation of Veterans Experiencing New Transient Neurological Symptoms

Vascular Health and Risk Factors in Children With Down Syndrome

Use of Preemptive Pudendal Nerve Block Prior to Hydrodistention for the Treatment of Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS)

The DETECT HCV Screening Trial

Development of a Power Training Program to Improve Mobility in Older Veterans

Pharmacokinetics of Zelquistinel in Fasted or Fed State

Ipatasertib (GDC-0068) Study to Evaluate Formulation Change and Food Effect on Bioavailability in Healthy Subjects

Pharmacokinetic Study of Oral Testosterone (T) Ester Formulations in Hypogonadal Men

Thorough QT/QTc (Corrected QT Interval) Study to Evaluate the Effect of Custirsen on Cardiac Repolarization

Pharmacokinetic Study Comparing Aspirin and Effervescent Aspirin

Vaccine Study for Tick-Borne Encephalitis Virus (TBEV)

Metabolic Syndrome Feasibility Study

Ph. II Treatment of Adults w Primary Malignant Glioma w Irinotecan + Temozolomide